Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering, Playtex Agree To Bring Suncare Ads In Line With FTC Guide

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough and Playtex should modify product advertising claiming "free" bonus amounts to facilitate third-party evaluation of such promotions, NAD states in its February Case Reports.

You may also be interested in...



Playtex Modifies Children's Sunscreen Ads In Response To CARU Concerns

Playtex Products has agreed to modify a TV advertisement for its children's sunscreen, Banana Boat Cool Colorz Vanishing Sunblock, in response to the Children's Advertising Review Unit's concern the commercial lacks the presence of a supervising adult figure.

Schering Antifungal "Free" Offers Not Exempt From FTC Rules - NAD

Schering-Plough's year-round offers of "bonus" sizes of Lotrimin AF and Tinactin topical antifungal products are not exempt from Federal Trade Commission rules regarding the timing of "free" offers, the National Advertising Division of the Council of Better Business Bureaus concludes in its January case report.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel